Teacher Retirement System of Texas Buys 6,805 Shares of Repligen Co. (NASDAQ:RGEN)

Teacher Retirement System of Texas lifted its stake in shares of Repligen Co. (NASDAQ:RGEN) by 229.1% in the fourth quarter, HoldingsChannel.com reports. The fund owned 9,775 shares of the biotechnology company’s stock after acquiring an additional 6,805 shares during the quarter. Teacher Retirement System of Texas’ holdings in Repligen were worth $1,407,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in RGEN. Conestoga Capital Advisors LLC lifted its stake in Repligen by 0.7% during the fourth quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company’s stock worth $136,395,000 after purchasing an additional 6,872 shares during the last quarter. DF Dent & Co. Inc. increased its position in shares of Repligen by 31.0% during the 3rd quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock valued at $87,852,000 after purchasing an additional 139,615 shares during the last quarter. New York State Common Retirement Fund raised its holdings in shares of Repligen by 2.5% during the 4th quarter. New York State Common Retirement Fund now owns 581,442 shares of the biotechnology company’s stock valued at $83,693,000 after buying an additional 14,398 shares in the last quarter. Stephens Investment Management Group LLC lifted its position in Repligen by 7.4% in the 4th quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company’s stock worth $77,267,000 after buying an additional 37,057 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its stake in Repligen by 79.9% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company’s stock worth $65,395,000 after buying an additional 203,011 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Price Performance

RGEN opened at $133.41 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The stock has a market capitalization of $7.49 billion, a PE ratio of -261.59, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95. The stock’s 50 day moving average price is $154.21 and its 200-day moving average price is $148.14. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $184.98.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. On average, equities research analysts predict that Repligen Co. will post 1.72 EPS for the current year.

Insider Buying and Selling

In other news, Director Margaret Pax bought 250 shares of Repligen stock in a transaction on Monday, March 17th. The shares were purchased at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the acquisition, the director now owns 1,043 shares of the company’s stock, valued at approximately $157,169.67. The trade was a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.20% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

RGEN has been the topic of several research reports. HC Wainwright reissued a “buy” rating and set a $180.00 price target on shares of Repligen in a research note on Friday, February 21st. StockNews.com cut shares of Repligen from a “hold” rating to a “sell” rating in a research report on Friday, February 21st. JPMorgan Chase & Co. upped their price target on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. TD Cowen initiated coverage on Repligen in a report on Monday, February 10th. They issued a “buy” rating and a $200.00 price objective on the stock. Finally, Evercore ISI assumed coverage on Repligen in a report on Tuesday, March 18th. They set an “in-line” rating and a $155.00 target price for the company. One research analyst has rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $178.64.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.